Endonovo TherapeuticsENDV Return-on-Tangible-Asset is -12,400.00% as of Jun. 2025. Among 1,413 Biotechnology companies, Endonovo Therapeutics ranks worse than 100.21% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Endonovo Therapeutics's annualizedNet Income for the quarter that ended in Jun. 2025 was $-2.23 Mil. Endonovo Therapeutics's average total tangible assets for the quarter that ended in Jun. 2025 was $0.02 Mil. Therefore, Endonovo Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2025 was -12,400.00%.
The historical rank and industry rank for Endonovo Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
ENDV's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -35.75 * Ranked among companies with meaningful Return-on-Tangible-Asset only.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Endonovo Therapeutics Return-on-Tangible-Asset Related Terms
Endonovo Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Endonovo Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDV vs RGBP, SIGY, CNBX: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Endonovo Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Endonovo Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Endonovo Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2025) net income data.
What does a Return-on-Tangible-Asset of -12,400.00% mean?
Endonovo Therapeutics (ENDV) has a Return-on-Tangible-Asset of -12,400.00% as of Jun. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #1416 out of 1413 companies in the Biotechnology industry.
Is Endonovo Therapeutics' Return-on-Tangible-Asset too high?
Endonovo Therapeutics' current Return-on-Tangible-Asset is -12,400.00%. Based on the distribution chart, Endonovo Therapeutics ranks #1416 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' Return-on-Tangible-Asset compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #1416 out of 1413 companies for Return-on-Tangible-Asset. This places Endonovo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current Return-on-Tangible-Asset is -12,400.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Return-on-Tangible-Asset of -12,400.00%. The current Return-on-Tangible-Asset is -12,400.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Return-on-Tangible-Asset is -12,400.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENDV has been successfully added to your 